Evidence map›Paper›PMID 33652659›Full record

ArticleCancers2021

Outcome of Stage IV Completely Necrotic Wilms Tumour and Local Stage III Treated According to the SIOP 2001 Protocol.

Raquel Dávila Fajardo, Rhoikos Furtwängler, Martine van Grotel, Harm van Tinteren, Claudia Pasqualini, Kathy Pritchard-Jones, Reem Al-Saadi, Beatriz de Camargo, Gema L Ramírez Villar, Norbert Graf and 7 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 6 countries.

Raquel Dávila FajardoDepartment of Radiation Oncology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands.ORCID 0000-0002-4729-825X
Rhoikos FurtwänglerDepartment of Paediatric Oncology and Haematology, University Hospital of Saarland, 66421 Homburg, Germany.
Martine van GrotelPrincess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.ORCID 0000-0002-8849-8573
Harm van TinterenTrial and Data Center, Princess Maxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
Claudia PasqualiniDepartment of Paediatric Oncology, Institute Gustave Roussy, CEDEX, 94805 Villejuif, France.
Kathy Pritchard-JonesDevelopmental Biology & Cancer Research & Teaching Department, UCL Great Ormond Street Institute of Child Health, London WC1N 1EH, UK.ORCID 0000-0002-2384-9475
Reem Al-SaadiDevelopmental Biology & Cancer Research & Teaching Department, UCL Great Ormond Street Institute of Child Health, London WC1N 1EH, UK.ORCID 0000-0002-0816-5649
Beatriz de CamargoResearch Center, Brazilian National Cancer Institute, Rio de Janeiro 20230-240, Brazil.ORCID 0000-0002-5794-1042
Gema L Ramírez VillarDepartment of Paediatric Oncology, Hospital Universitario Virgen del Rocío, 41013 Seville, Spain.ORCID 0000-0001-9986-5861
Norbert GrafDepartment of Paediatric Oncology and Haematology, University Hospital of Saarland, 66421 Homburg, Germany.ORCID 0000-0002-2248-323X
Xavier MuraccioleDepartment of Radiation Oncology, Assistance Publique Hôpitaux de Marseille, 13005 Marseille, France.
Patrick MelchiorDepartment of Radiation Oncology, University Hospital of Saarland, 66421 Homburg, Germany.
Daniel SaundersThe Christie NHS Foundation Trust, Manchester M20 4BX, UK.ORCID 0000-0003-0151-1155
Christian RübeDepartment of Radiation Oncology, University Hospital of Saarland, 66421 Homburg, Germany.
Marry M van den Heuvel-EibrinkPrincess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
Geert O JanssensDepartment of Radiation Oncology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands.
Arnauld C VerschuurDepartment of Paediatric Oncology, La Timone Children's Hospital, Assistance Publique Hôpitaux de Marseille, 13005 Marseille, France.
Saarland University · DEPrincess Máxima Center · NLAssistance Publique Hôpitaux de Marseille · FRGreat Ormond Street Hospital · GBUniversity Medical Center Utrecht · NLHospital Universitario Virgen del Rocío · ESInstitut Gustave Roussy · FRInstituto Nacional de Câncer - INCA · BRThe Christie NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWilms tumour (WT) patients with a localised completely necrotic nephroblastoma after preoperative chemotherapy are a favourable outcome group. Since the introduction of the SIOP 2001 protocol, the SIOP- Renal Tumour Study Group (SIOP-RTSG) has omitted radiotherapy for such patients with low-risk, local stage III in an attempt to reduce treatment burden. However, for metastatic patients with local stage III, completely necrotic WT, the recommendations led to ambiguous use. The purpose of this descriptive study is to demonstrate the outcomes of patients with metastatic, completely necrotic and local stage III WT in relation to the application of radiotherapy or not. METHODS AND MATERIALS: all metastatic patients with local stage III, completely necrotic WT after 6 weeks of preoperative chemotherapy who were registered in the SIOP 2001 study were included in this analysis. The pattern of recurrence according to the usage of radiation treatment and 5 year event-free survival (EFS) and overall survival (OS) was analysed.

resultsseven hundred and three metastatic WT patients were registered in the SIOP 2001 database. Of them, 47 patients had a completely necrotic, local stage III WT: 45 lung metastases (11 combined localisations), 1 liver/peritoneal, and 1 tumour thrombus in the renal vein and the inferior vena cava with bilateral pulmonary arterial embolism. Abdominal radiotherapy was administered in 29 patients (62%; 29 flank/abdominal irradiation and 9 combined with lung irradiation). Eighteen patients did not receive radiotherapy. Median follow-up was 6.6 years (range 1-151 months). Two of the 47 patients (4%) developed disease recurrence in the lung (one combined with abdominal relapse) and eventually died of the disease. Both patients had received abdominal radiotherapy, one of them combined with lung irradiation. Five-year EFS and OS were 95% and 95%, respectively.

conclusionsthe outcome of patients with stage IV, local stage III, completely necrotic Wilms tumours is excellent. Our results suggest that abdominal irradiation in this patient category may not be of added value in first-line treatment, consistent with the current recommendation in the SIOP-RTSG 2016 UMBRELLA protocol.

Indexed as

completely necroticmetastatic diseasenephroblastomaWilms tumour

Identifiers

PMID33652659
PMCPMC7956604
OpenAlexW3133934957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.